𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Intrahepatic cholestasis of pregnancy: A randomized controlled trial comparing dexamethasone and ursodeoxycholic acid

✍ Scribed by Anna Glantz; Hanns-Ulrich Marschall; Frank Lammert; Lars-Åke Mattsson


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
123 KB
Volume
42
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


Intrahepatic cholestasis of pregnancy (ICP) is characterized by troublesome maternal pruritus, elevated serum bile acids (> or =10 micromol/L) and increased fetal risk. Recently we determined a cutoff level of serum bile acids, > or =40 micromol/L, to be associated with impaired fetal outcome. We have now studied the effects of ursodeoxycholic acid (UDCA) and dexamethasone on pruritus, biochemical markers of cholestasis, and fetal complication rates in a double-blind, placebo-controlled trial. For this purpose, 130 women with ICP were randomly allocated to UDCA (1 g/day for three weeks), or dexamethasone (12 mg/day for 1 week and placebo during weeks 2 and 3), or placebo for 3 weeks. Pruritus and biochemical markers of cholestasis were analyzed at inclusion and after 3 weeks of treatment. Fetal complications (spontaneous preterm delivery; asphyxial events; and meconium staining of amniotic fluid, placenta, and membranes) were registered at delivery. An intention-to-treat analysis showed significant reduction of alanine aminotransferase (ALT) (P = .01) and bilirubin (P = .002) in the UDCA group only. In a subgroup analysis of ICP women with serum bile acids > or =40 micromol/L at inclusion (n = 34), UDCA had significant effects on pruritus (-75%), bile acids (-79%), ALT (-80%), and bilirubin (-50%) as well, but not on fetal complication rates. Dexamethasone yielded no alleviation of pruritus or reduction of ALT and was less effective than UDCA at reducing bile acids and bilirubin. In conclusion, 3 weeks of UDCA treatment improved some biochemical markers of ICP irrespective of disease severity, whereas significant relief from pruritus and marked reduction of serum bile acids were only found in patients with severe ICP.


📜 SIMILAR VOLUMES


A randomized trial comparing colchicine
✍ R E Poupon; P M Huet; R Poupon; A Bonnand; J T Van Nhieu; E S Zafrani 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 2 views

The efficacy of colchicine combined with ursodeoxycholic acid (UDCA) and UDCA alone in the treatment of patients with nonadvanced primary biliary cirrhosis (PBC) was evaluated in a 2-year controlled study. Seventy-four patients with PBC who had been treated previously with UDCA (at least 8 months) b

Progesterone metabolites and bile acids
✍ L Meng; H Reyes; M Axelson; J Palma; I Hernandez; J Ribalta; J Sjovall 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB 👁 1 views

The concentrations in serum of sulfated metabolites of pro-Intrahepatic cholestasis of pregnancy (ICP) is charactergesterone are known to be elevated in patients with intraheized by skin pruritus appearing in late pregnancy, coinciding patic cholestasis of pregnancy (ICP). The profiles of these with

Metronidazole and ursodeoxycholic acid f
✍ Martti Färkkilä; Anna-Liisa Karvonen; Heimo Nurmi; Hannu Nuutinen; Matti Taavits 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

No effective medical therapy is currently available for primary sclerosing cholangitis (PSC). Ursodeoxycholic acid (UDCA) improves liver enzymes, but its effect on liver histology is controversial. Metronidazole (MTZ) prevents PSC-like liver damage in animal models and reduces intestinal permeabilit

Ursodeoxycholic acid for treatment of no
✍ Keith D. Lindor; Kris V. Kowdley; E. Jenny Heathcote; M. Edwyn Harrison; Roberta 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy-proven NASH to receive between 13 and 15 mg/kg/d of